Cell and Gene Outsourcing

  1. Candidate Screening And Feasibility Studies For Viral Gene Therapies

    Create a simple, modular path to cGMP manufacturing that minimizes risk. Explore a strategic approach for early-stage development and how it can propel therapies to the clinic and the market.

  2. Characterizing AAV Encapsidated Nucleic Acid Sequences Using NGS 8/11/2023

    Here, we discuss the characterization of several representative AAV molecules using next-generation sequencing (NGS), including the sequencing process, bioinformatic analysis, and representative results.

  3. Meet The Experts: PAT, Raman Spectroscopy, And Chemometrics 4/14/2023

    Gain a better understanding of process analytical technology (PAT), Raman spectroscopy, chemometrics, and Raman applications in bioprocessing.

  4. An Early Formulation Screening Service 5/23/2024

    Gain insights into overcoming the challenges in lipid nanoparticle (LNP) formulation, explore critical aspects of the process and analytical development of LNPs, and much more.

  5. Identify And Quantify AAV Fill States Using Analytical Ultracentrifugation 3/14/2024

    Explore how to implement analysis using sedimentation velocity analytical ultracentrifugation to characterize AAV size distributions and multiple detection wavelengths to identify various fill states in AAV preparation.

  6. Bio4C ProcessPad™ Product Overview 5/19/2020

    Introducing Bio4C ProcessPad™ Software, part of the BioContinuum™ Platform.

  7. How To Bring Your LNP Formulation To Clinical/Commercial Manufacturing

    Gain valuable insights into key considerations when selecting lipid excipients for LNP formulations and the process development steps necessary to advance them to GMP manufacturing and clinical trials.

  8. Early Developability And Analytical Toolbox For The Production Of Multi-Chain Biotherapeutics

    In recent years, the number of biotherapeutic molecules requiring more complex assemblies has greatly increased. Typically, these multi-chain molecules are no longer compatible with platform approaches and require a more agile approach to early developability and method development.

  9. Navigating The Complex Landscape Of Lentiviral Vector Quality Control 6/26/2025

    Explore the latest in lentiviral vector release testing, which covers biosafety, regulatory insights, and QC strategies to ensure patient safety and accelerate your path to clinic.

  10. Combining Expertise With Best-In-Class Technology 10/20/2021

    Members of the MilliporeSigma leadership team reflect on the longstanding experience of our BioReliance® viral vector manufacturing facilities. Our legacy experience, alongside our brand new facility and latest industry innovations, ensure we are a preferred partner to pioneer the path to cures.